Shuttle Pharmaceuticals Holdings Inc (SHPH)
1.62
-0.05
(-2.99%)
USD |
NASDAQ |
Nov 04, 16:00
1.60
-0.02
(-1.23%)
After-Hours: 20:00
Shuttle Pharmaceuticals Holdings Research and Development Expense (TTM): 2.805M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.805M |
| March 31, 2024 | 2.999M |
| December 31, 2023 | 3.334M |
| September 30, 2023 | 2.900M |
| June 30, 2023 | 2.429M |
| March 31, 2023 | 1.673M |
| Date | Value |
|---|---|
| December 31, 2022 | 1.047M |
| September 30, 2022 | 1.491M |
| June 30, 2022 | 1.009M |
| March 31, 2022 | 1.212M |
| December 31, 2021 | 1.022M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
1.009M
Minimum
Jun 2022
3.334M
Maximum
Dec 2023
1.993M
Average
1.673M
Median
Mar 2023
Research and Development Expense (TTM) Benchmarks
| Oragenics Inc | 13.38M |
| Soligenix Inc | 3.232M |
| Tonix Pharmaceuticals Holding Corp | 60.73M |
| Lixte Biotechnology Holdings Inc | 0.6113M |
| NovaBay Pharmaceuticals Inc | 0.043M |